# Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)

> **NCT07668271** · PHASE4 · RECRUITING · sponsor: **Xiamen Innovax Biotech Co., Ltd** · enrollment: 720 (estimated)

## Conditions studied

- Infection by Human Papilloma Virus

## Interventions

- **BIOLOGICAL:** 9-valent HPV vaccine (Cecolin 9)

## Key facts

- **NCT ID:** NCT07668271
- **Lead sponsor:** Xiamen Innovax Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-26
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668271, "Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*